U.S. FDA GRAS for Food Ingredients: GRAS Notification, Self-Affirmed GRAS

What Is U.S. GRAS?

GRAS (Generally Recognized As Safe) is a key safety determination mechanism administered by the U.S. Food and Drug Administration (FDA) for food ingredients entering the U.S. market.

A substance is considered GRAS if, under its intended conditions of use (specified food categories, use levels, target populations, and intended purposes), qualified experts in toxicology, food science, and related fields generally recognize it as safe based on scientific evidence and consensus.

U.S. GRAS Certification vs. Other FDA Regulatory Paths

GRAS is an important pathway for food ingredients in the U.S. market, but it is not suitable for every substance. Before starting a GRAS project, companies should confirm whether the product is intended for conventional food, dietary supplements, food additives, color additives, food contact materials, or another regulated category.

A GRAS assessment should always be made based on the product’s actual use, composition, and regulatory purpose.

Types of U.S. GRAS Routes: Self-Affirmed GRAS and FDA GRAS Notification

Companies typically consider GRAS through two commercial routes: Self-Affirmed GRAS and FDA GRAS Notification.

1. Self-Affirmed GRAS

Self-Affirmed GRAS means that a company concludes, based on adequate scientific evidence and general recognition among qualified experts, that the intended use of its substance is GRAS.

Self-Affirmed GRAS is generally not submitted to FDA and is not publicly listed in FDA’s GRAS Notice Inventory. However, the company remains responsible for ensuring that the GRAS conclusion is scientifically sound, complete, and legally defensible.

2. FDA GRAS Notification

FDA GRAS Notification is a voluntary submission of a GRAS Notice to FDA for review under 21 CFR Part 170, Subpart E. FDA generally reviews a filed GRAS notice within 180 days, with a possible 90-day extension when needed.

After FDA evaluates a filed GRAS notice, the agency may issue a response letter. A commercially favorable outcome is commonly referred to as a “no questions letter”, meaning FDA has no questions at that time regarding the notifier’s conclusion that the substance is GRAS under the intended conditions of use.

However, this should not be described as “FDA approval.” FDA response letters commonly state that the agency has not made its own determination regarding the GRAS status of the subject use. The notifier remains responsible for ensuring that the marketed ingredient is safe and compliant.

Which Route Is Better for Overseas Companies?

For overseas ingredient companies, FDA GRAS Notification is often preferred when U.S. customers, distributors, strategic partners, investors, or major food brands require a higher level of regulatory transparency.

Self-affirmed GRAS may work well for companies that want a faster internal compliance route and stronger protection of confidential information. FDA GRAS Notification is often more suitable when the goal is broader commercial acceptance, customer diligence support, and stronger market recognition.

What a GRAS Dossier Usually Includes

Before preparing a U.S. GRAS conclusion or FDA GRAS Notification, companies usually need to build a scientific evidence package around several core questions:

What is the substance? How is it manufactured? Where will it be used? How much will consumers consume? Why is it safe?

Typical information includes:

U.S. GRAS Process, Timeline and Cost Reference

The timeline and cost of a GRAS project depend on the substance type, data availability, manufacturing complexity, toxicology requirements, dietary exposure complexity, and whether FDA GRAS Notification is pursued.

Core Process

• Feasibility Assessment and Data Gap Analysis
  Evaluate whether the available data are sufficient to support a GRAS conclusion and determine whether additional testing is needed.

• Document Preparation and Dossier Drafting
  Prepare the GRAS dossier in English, including substance identity, manufacturing process, dietary exposure assessment, toxicology data review, and safety narrative.

• Expert Panel Review
  Organize an expert panel composed of independent experts in relevant fields such as toxicology and food science. The expert panel reviews the evidence and issues a consensus statement. At this stage, a self-affirmed GRAS conclusion may be completed.

• FDA GRAS Notification
  If FDA review is needed, the GRAS dossier is submitted to FDA as a GRAS Notice.

• FDA Review and Response
  FDA reviews the notice and, if it has no questions, issues a “no questions letter.” FDA’s response timeframe is 180 days after filing, with a possible 90-day extension when needed.

Timeline and Cost Estimate

• Self-Affirmed GRAS
  The overall process usually takes about 4 months. The actual timeline may vary depending on the complexity of the substance, manufacturing process, and amount of publicly available data. Costs mainly include consulting service fees and expert panel review fees.

• FDA GRAS Notification
  Based on the completion of self-affirmed GRAS, companies need to allow additional time for FDA review, usually 6–9 months. The overall project timeline is commonly around 1–1.5 years. FDA currently does not charge an official review user fee for GRAS Notification, but companies need to consider additional consulting and technical support costs for responding to FDA questions.

• Additional Testing Costs
  If the existing toxicology data are insufficient, additional subchronic toxicity or genotoxicity studies may be required. This will result in additional third-party laboratory costs and several months of testing time.

Note: A specific quotation should be assessed case by case based on the characteristics of the ingredient.

Which Companies Should Prioritize GRAS Assessment?

The following companies should consider GRAS assessment early in product development, commercialization, or U.S. market entry planning.

• Probiotics / Postbiotics: such as Lactobacillus rhamnosus, Bifidobacterium animalis, Bifidobacterium lactis, Bacillus coagulans, inactivated lactic acid bacteria, and short-chain fatty acid metabolites.
  

• HMOs / Oligosaccharides: such as 2’-fucosyllactose, LNnT, fructooligosaccharides, galactooligosaccharides, and isomaltooligosaccharides.
  

• Enzymes: such as amylase, protease, lipase, pectinase, lactase, and glucose oxidase.
  

• Sugar Substitutes / Sweeteners: such as erythritol, allulose, steviol glycosides, monk fruit sweeteners, xylitol, and sucralose.
  

• Botanical Extracts: such as ginseng extract, green tea extract, turmeric extract, grape seed extract, and elderberry extract.
  

• Synthetic Biology Ingredients: such as NMN, ergothioneine, squalene, steviol glycosides, and human milk oligosaccharides produced by engineered microbial fermentation.
  

• Fermentation-Derived Proteins and Novel Proteins: such as precision fermentation whey protein, fermentation-derived heme protein, single-cell protein, fermented pea protein, insect protein, and microalgae protein.
  

These ingredients usually involve higher technical complexity, stricter customer review, and more demanding documentation requirements. The earlier companies conduct regulatory pathway assessment, the easier it is to align R&D, testing, documentation preparation, and market launch planning.

Can an Existing GRAS Notice Be Used?

Finding a similar substance in FDA’s GRAS Notice Inventory does not automatically mean that your ingredient can rely on that GRAS conclusion.

A GRAS notice is tied to a specific notified substance, notifier, manufacturing process, specifications, intended use, use levels, and exposure assessment. Even if your ingredient appears similar, a new assessment may be needed if there are material differences.

Companies should reassess GRAS applicability when:

• The intended food categories are different.

• Use levels are higher.

• Total dietary exposure changes.

• The target population differs.

• The manufacturing process changes.

• The source material, strain, purity, or specifications differ.

• The impurity profile or residual by-products differ.

• New toxicological or regulatory concerns emerge.

• U.S. customers, retailers, investors, or distributors require an independent compliance file.

Existing GRAS notices can be useful references, but they should not replace a product-specific regulatory assessment.

U.S. GRAS Regulatory Trend

The U.S. food chemical and food ingredient regulatory environment is becoming more transparent and more risk-based.

FDA’s Human Foods Program 2026 Priority Deliverables state that FDA plans to publish a proposed regulation in 2026 to require the submission of GRAS notices for all new substances claimed to be GRAS. This signals a potentially significant shift in the future commercial acceptability of purely self-determined GRAS conclusions.

For food ingredient companies, this means:

• Self-Affirmed GRAS may face higher transparency expectations;

• FDA GRAS Notification may become more important in customer due diligence;

• new ingredients, synthetic biology materials, fermentation-derived ingredients, and novel proteins may require stronger safety packages;

• existing products may need renewed documentation review; and

• U.S. buyers may increasingly request formal GRAS, NDI, or food additive pathway evidence.

Even before any final rule is issued, companies planning long-term U.S. market entry should build a complete, reviewable, and scientifically defensible safety evidence chain.

How REACH24H Supports U.S. GRAS Projects

REACH24H supports global food, food ingredient, nutrition, dietary supplement, and synthetic biology companies with U.S. food ingredient compliance strategy and GRAS project execution.

Our services include:

• U.S. Food Ingredient Regulatory Path Determination & GRAS Feasibility Assessment

• GRAS Data Gap Analysis

• FDA GRAS Notification Submission

• Self-affirmed GRAS Expert Panel Review Support

• Toxicological & Dietary Exposure Assessment

• GMM / Synthetic Biology Ingredient Compliance Assessment

• FDA Inquiry Response & U.S. Customer Supply Chain Audit Support

Why Partner with REACH24H?

Our technical team includes professionals with advanced degrees from leading global research institutions and expertise in chemistry, toxicology, food science, microbiology, pharmacy, and related disciplines. Team credentials include U.S. regulatory affairs specialists, Diplomates of the American Board of Toxicology (DABT), European Registered Toxicologists (ERT), and toxicologists certified by the Royal Society of Biology and the British Toxicology Society.

We have extensive GRAS project experience across HMOs, probiotics, novel proteins, fermentation-derived ingredients, synthetic biology ingredients, enzymes, and sweeteners, supporting a wide range of fermentation-based and synthetic production pathways.

U.S. GRAS FAQ

Access Your Free Resource: Regulatory Pathways for Novel Food Ingredients Worldwide

We are pleased to introduce our Regulatory Pathways for Novel Food Ingredients Worldwide. This guide provides a systematic overview of the regulatory frameworks for novel food ingredients in key markets, including China, the USA, the EU, Australia-New Zealand, Japan, South Korea, and Southeast Asia.

Key sections include:

• Regulatory Frameworks & Authorities

• Approval Processes & Documentation

• Key Compliance Strategies